|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Precision_Genome_Engineering,_Inc.
|
|
gptkbp:category
|
gptkb:biotechnology
gptkb:public_company
American company
company based in Massachusetts
company listed on NASDAQ
|
|
gptkbp:CEO
|
gptkb:Andrew_Obenshain
|
|
gptkbp:focusesOn
|
genetic disorders
rare diseases
gene therapy
|
|
gptkbp:founded
|
1992
|
|
gptkbp:founder
|
gptkb:Nick_Leschly
gptkb:Mitchell_Finer
gptkb:Philippe_Leboulch
|
|
gptkbp:headquartersLocation
|
gptkb:Somerville,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bluebird bio
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:notableCase
|
gene therapy for beta-thalassemia
gene therapy for cerebral adrenoleukodystrophy
gene therapy for sickle cell disease
|
|
gptkbp:notableEvent
|
spun off oncology business as 2seventy bio in 2021
|
|
gptkbp:notableProduct
|
gptkb:Zynteglo
gptkb:LentiGlobin
gptkb:Skysona
gptkb:beti-cel
eli-cel
|
|
gptkbp:numberOfEmployees
|
~400 (2023)
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:regulates
|
Skysona approved by EMA in 2021
Skysona approved by FDA in 2022
Zynteglo approved by EMA in 2019
Zynteglo approved by FDA in 2022
|
|
gptkbp:servesArea
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:specializesIn
|
gene editing
gene therapy
|
|
gptkbp:spinOff
|
gptkb:2seventy_bio
|
|
gptkbp:stockSymbol
|
gptkb:BLUE
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.bluebirdbio.com/
|
|
gptkbp:bfsParent
|
gptkb:Zynteglo
gptkb:Abecma
|
|
gptkbp:bfsLayer
|
6
|